Tables S2 from Multilevel Regulation of Β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Hanyu Rao,Xiaoxue Li,Min Liu,Jing Liu,Wenxin Feng,Huayuan Tang,Jin Xu,Wei-Qiang Gao,Li

DOI: https://doi.org/10.1158/0008-5472.22428972

2023-01-01

Abstract:The information of the ChIP-seq peaks.

What problem does this paper attempt to address?

Table S1 from Multilevel Regulation of Β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Hanyu Rao,Xiaoxue Li,Min Liu,Jing Liu,Wenxin Feng,Huayuan Tang,Jin Xu,Wei-Qiang Gao,Li

DOI: https://doi.org/10.1158/0008-5472.22428978.v1

2023-01-01

Abstract:The information of the primers used in mRNA detection.
Figure S4 from Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Hanyu Rao,Xiaoxue Li,Min Liu,Jing Liu,Weiyue Feng,Huayuan Tang,Jing Xu,Wei‐Qiang Gao,Li Li

DOI: https://doi.org/10.1158/0008-5472.22428987

2023-01-01

Abstract:SETD2 overexpression did not change the protein level of S33Y.β-catenin.
Single-cell Multiomics Analysis Reveals Regulatory Programs in Clear Cell Renal Cell Carcinoma

Zhilin Long,Chengfang Sun,Min Tang,Yin Wang,Jiayan Ma,Jichuan Yu,Jingchao Wei,Jianzhu Ma,Bohan Wang,Qi Xie,Jiaming Wen

DOI: https://doi.org/10.1038/s41421-022-00415-0

IF: 38.079

2022-01-01

Cell Discovery

Abstract:The clear cell renal cell carcinoma (ccRCC) microenvironment consists of many different cell types and structural components that play critical roles in cancer progression and drug resistance, but the cellular architecture and underlying gene regulatory features of ccRCC have not been fully characterized. Here, we applied single-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) to generate transcriptional and epigenomic landscapes of ccRCC. We identified tumor cell-specific regulatory programs mediated by four key transcription factors (TFs) (HOXC5, VENTX, ISL1, and OTP), and these TFs have prognostic significance in The Cancer Genome Atlas (TCGA) database. Targeting these TFs via short hairpin RNAs (shRNAs) or small molecule inhibitors decreased tumor cell proliferation. We next performed an integrative analysis of chromatin accessibility and gene expression for CD8+ T cells and macrophages to reveal the different regulatory elements in their subgroups. Furthermore, we delineated the intercellular communications mediated by ligand-receptor interactions within the tumor microenvironment. Taken together, our multiomics approach further clarifies the cellular heterogeneity of ccRCC and identifies potential therapeutic targets.
SETD2 deficiency impairs β-catenin destruction complex to facilitate renal cell carcinoma formation

Hanyu Rao,Xiaoxue Li,Min Liu,Jing Liu,Wenxin Feng,Jin Xu,Wei-Qiang Gao,Li Li

DOI: https://doi.org/10.1101/2020.07.13.200220

2020-01-01

Abstract:Clear cell renal cell carcinoma (ccRCC) is a largely incurable disease that is highly relevant to epigenetic regulation including histone modification and DNA methylation. SET domain–containing 2 (SETD2) is a predominant histone methyltransferase catalyzing the trimethylation of histone H3 Lysine 36 (H3K36me3) and its mutations are highly relevant to clear cell renal cell carcinoma (ccRCC). However, its physiology role in ccRCC remains largely unexplored. Here we report that Setd2 deletion impairs the β-catenin destruction complex to facilitate ccRCC formation in a c-MYC-generated polycystic kidney disease (PKD) model, which can be relieved by an inhibitor of β-catenin-responsive transcription. Clinically, SETD2 loss is widely observed in ccRCC samples, and negatively correlated with expression of some members of β-catenin destruction complex, but positively correlated with the activation of Wnt/β-catenin signaling. Our findings thus highlight a previously unrecognized role of SETD2-mediated H3K36me3 modification in regulation of Wnt/β-catenin pathway in ccRCC.
Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395233

2023-01-01

Abstract:Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Table S3, S5-S7, S10-S18, S21 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Zhenyuan Yu,Yufang Lv,Cheng Su,Wenhao Lu,RuiRui Zhang,Jiaping Li,Bingqian Guo,Haibiao Yan,Deyun Liu,Zhanbin Yang,Hua Mi,Linjian Mo,Yi Guo,Wenyu Feng,Haotian Xu,Wenyi Peng,Jiwen Cheng,Aruo Nan,Zengnan Mo

DOI: https://doi.org/10.1158/0008-5472.22433229.v1

2023-01-01

Abstract:Table S3, S5-S7, S10-S18, S21
Supplementary Table S2 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Han Yin,Chunxia Qin,Qiang Wang,Yun Du,Xuanming Ding,Tao Xu,Xiaowei Zhang,Qing Li,Shijun Liu

DOI: https://doi.org/10.1158/1535-7163.22509592

2023-01-01

Abstract:Information of antibodies used in the present study
Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.

Lin Li,Weili Miao,Ming Huang,Preston Williams,Yinsheng Wang

DOI: https://doi.org/10.1074/mcp.ra118.000957

2018-01-01

Abstract:Clear cell renal cell carcinoma (ccRCC) is the most common type of RCC in humans. SET domain-containing 2 (SETD2), a lysine methyltransferase for histone and other proteins, has been found to be frequently lost in ccRCC. However, the mechanisms through which deficiency in SETD2 contributes to ccRCC development remain largely unknown. Here, we used a human embryonic kidney epithelial cell line with the SETD2 gene being knocked out using CRISPR/Cas9 technology. Using ChIP-seq analysis, we showed that SETD2 loss leads to diminished occupancy of histone H3K36me3 and H4K16ac on actively transcribed genes. Transcriptome sequencing of the knockout cells revealed diminished expression of genes involved in metabolic pathways and elevated expression of genes involved in regulation of RNA polymerase II-mediated transcription. Quantitative proteomic analysis of chromatin-associated proteins showed that genetic ablation of SETD2 leads to elevated chromatin occupancy of proteins involved in chromatin remodeling and RNA polymerase II transcription regulation, and diminished chromatin binding of proteins involved in translation elongation and RNA splicing. Interestingly, we found that SETD2 depletion attenuates cell proliferation, and this can be rescued by knockdown of CDK1. Taken together, we illustrate multiple SETD2-regulated cellular pathways that suppress cancer development and uncover mechanisms underlying aberrant cell cycle regulation in SETD2-depleted cells.
Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

Mengxue Yu,Kaiyu Qian,Gang Wang,Yu Xiao,Yuan Zhu,Lingao Ju

DOI: https://doi.org/10.3389/fonc.2023.1114461

IF: 4.7

2023-03-22

Frontiers in Oncology

Abstract:SET domain-containing 2 (SETD2) is a lysine methyltransferase that catalyzes histone H3 lysine36 trimethylation (H3K36me3) and has been revealed to play important roles in the regulation of transcriptional elongation, RNA splicing, and DNA damage repair. SETD2 mutations have been documented in several cancers, including clear cell renal cell carcinoma (ccRCC). SETD2 deficiency is associated with cancer occurrence and progression by regulating autophagy flux, general metabolic activity, and replication fork speed. Therefore, SETD2 is considered a potential epigenetic therapeutic target and is the subject of ongoing research on cancer-related diagnosis and treatment. This review presents an overview of the molecular functions of SETD2 in H3K36me3 regulation and its relationship with ccRCC, providing a theoretical basis for subsequent antitumor therapy based on SETD2 or H3K36me3 targets.

oncology
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Table S1, S2, S4 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Zhenyuan Yu,Yufang Lv,Cheng Su,Wenhao Lu,RuiRui Zhang,Jiaping Li,Bingqian Guo,Haibiao Yan,Deyun Liu,Zhanbin Yang,Hua Mi,Linjian Mo,Yi Guo,Wenyu Feng,Haotian Xu,Wenyi Peng,Jiwen Cheng,Aruo Nan,Zengnan Mo

DOI: https://doi.org/10.1158/0008-5472.22433238.v1

2023-01-01

Abstract:<p>Details of each sample</p>
Supplementary Table S1 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Yin Huaqi,Qin Caipeng,Wang Qiang,Du Yiqing,Dai Xiang,Tang Xu,Zhang Xiaowei,Li Qing,Liu Shijun,Xu Tao

DOI: https://doi.org/10.1158/1535-7163.22509595.v1

2023-01-01

Abstract:Clinicopathological characteristics of patients with ccRCC
Supplementary Table S4 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Yin Huaqi,Qin Caipeng,Wang Qiang,Du Yiqing,Dai Xiang,Tang Xu,Zhang Xiaowei,Li Qing,Liu Shijun,Xu Tao

DOI: https://doi.org/10.1158/1535-7163.22509586.v1

2023-01-01

Abstract:Univariable and multivariable analysis for ccRCC patients' overall survival using Cox's proportional hazards model
Table S8 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Zhenyuan Yu,Yufang Lv,Cheng Su,Wenhao Lu,RuiRui Zhang,Jiaping Li,Bingqian Guo,Haibiao Yan,Deyun Liu,Zhanbin Yang,Hua Mi,Linjian Mo,Yi Guo,Wenyu Feng,Haotian Xu,Wenyi Peng,Jiwen Cheng,Aruo Nan,Zengnan Mo

DOI: https://doi.org/10.1158/0008-5472.22433226.v1

2023-01-01

Abstract:SNV was detected by whole-exome sequencing of 19 ccRCC samples.
Table S20 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Zhenyuan Yu,Yufang Lv,Cheng Su,Wenhao Lu,RuiRui Zhang,Jiaping Li,Bingqian Guo,Haibiao Yan,Deyun Liu,Zhanbin Yang,Hua Mi,Linjian Mo,Yi Guo,Wenyu Feng,Haotian Xu,Wenyi Peng,Jiwen Cheng,Aruo Nan,Zengnan Mo

DOI: https://doi.org/10.1158/0008-5472.22433232

2023-01-01

Abstract:<p>qPCR results after ASO (5717 and 5608) treatment of 2 lncRNAs in caki-2 and 786-O cell lines.Three or six PCR by-wells were prepared for each sample. NC, negative control.</p>
Revealing the characteristics of SETD2-mutated clear cell renal cell carcinoma through tumor heterogeneity analysis

Shansen Peng,Zhouzhou Xie,Huiming Jiang,Guihao Zhang,Nanhui Chen

DOI: https://doi.org/10.3389/fgene.2024.1447139

IF: 3.7

2024-07-25

Frontiers in Genetics

Abstract:Background: Renal cell carcinoma (RCC) is the most prevalent type of malignant kidney tumor in adults, with clear cell renal cell carcinoma (ccRCC) comprising about 75% of all cases. The SETD2 gene, which is involved in the modification of histone proteins, is often found to have alterations in ccRCC. Yet, our understanding of how these SETD2 mutations affect ccRCC characteristics and behavior within the tumor microenvironment is still not fully understood. Methods: We conducted a detailed analysis of single-cell RNA sequencing (scRNA-seq) data from ccRCC. First, the data was preprocessed using the Python package, "scanpy." High variability genes were pinpointed through Pearson's correlation coefficient. Dimensionality reduction and clustering identification were performed using Principal Component Analysis (PCA) and the Leiden algorithm. Malignant cell identification was conducted with the "InferCNV" R package, while cell trajectories and intercellular communication were depicted using the Python packages "VIA" and "cellphoneDB." We then employed the R package "Deseq2" to determine differentially expressed genes (DEGs) between groups. Using high-dimensional weighted gene correlation network analysis (hdWGCNA), co-expression modules were identified. We intersected these modules with DEGs to establish prognostic models through univariate Cox and the least absolute shrinkage and selection operator (LASSO) method. Results: We identified 69 and 53 distinctive cell clusters, respectively. These were classified further into 12 unique cell types. This analysis highlighted the presence of an abnormal tumor sub-cluster (MT + group), identified by high mitochondrial-encoded protein gene expression and an indication of unfavorable prognosis. Investigation of cellular interactions spotlighted significant interactions between the MT + group and endothelial cells, macrophaes. In addition, we developed a prognostic model based on six characteristic genes. Notably, risk scores derived from these genes correlated significantly with various clinical features. Finally, a nomogram model was established to facilitate more accurate outcome prediction, incorporating four independent risk factors. Conclusion: Our findings provide insight into the crucial transcriptomic characteristics of ccRCC associated with SETD2 mutation. We discovered that this mutation-induced subcluster could stimulate M2 polarization in macrophages, suggesting a heightened propensity for metastasis. Moreover, our prognostic model demonstrated effectiveness in forecasting overall survival for ccRCC patients, thus presenting a valuable clinical tool.

genetics & heredity
Supplementary Table 2 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Zhenyu Liu,Yuqiong Hu,Haoling Xie,Kexuan Chen,Lu Wen,Wei Fu,Xin Zhou,Fuchou Tang

DOI: https://doi.org/10.1158/2159-8290.25956957

2024-01-01

Abstract:Supplementary Table 2. Quality metrics, cell type annotation, and patient composition of each epithelium cluster.
Supplemental Table 2 from KLF6 Suppresses Metastasis of Clear Cell Renal Cell Carcinoma Via Transcriptional Repression of E2F1

Yu Gao,Hongzhao Li,Xin Ma,Yang Fan,Dong Ni,Yu Zhang,Qingbo Huang,Kan Liu,Xintao Li,Lei Wang,Liangyou Gu,Yuanxin Yao,Qing Ai,Qingshan Du,Erlin Song,Xu Zhang

DOI: https://doi.org/10.1158/0008-5472.22415033.v1

2023-01-01

Abstract:The comparison of KLF6 expressions in Non-metastatic and Metastatic specimens by immunohistochemical staining.
Supplementary Tables from A Feedback Circuitry Between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis

Kun Liu,Shuye Deng,Xu Li,Wei Pan,Shiyu Yang,Fufu Zheng,Xingui Wu,Hongrong Hu,Zhijun Liu,Junhang Luo,Rui Zhang,Dong‐Ming Kuang,Jiajun Dong,Yi Wu,Hui Zhang,Penghui Zhou,Jin‐Xin Bei,Yang Xu,Jianping Yin,Peng Wang,Huai‐Qiang Ju,Rui‐Hua Xu,Bo Li

DOI: https://doi.org/10.1158/0008-5472.22425276

2023-01-01

Abstract:Supplementary tables S1-S4 show analytic details of the ENCODE ChIP-Seq data and TCGA RNA-Seq data, together with primer sequences used in this study.

Tables S2 from Multilevel Regulation of Β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Table S1 from Multilevel Regulation of Β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Figure S4 from Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Single-cell Multiomics Analysis Reveals Regulatory Programs in Clear Cell Renal Cell Carcinoma

SETD2 deficiency impairs β-catenin destruction complex to facilitate renal cell carcinoma formation

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Table S3, S5-S7, S10-S18, S21 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Supplementary Table S2 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Table S1, S2, S4 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Supplementary Table S1 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Supplementary Table S4 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects

Table S8 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Table S20 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma

Revealing the characteristics of SETD2-mutated clear cell renal cell carcinoma through tumor heterogeneity analysis

Supplementary Table 2 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Supplemental Table 2 from KLF6 Suppresses Metastasis of Clear Cell Renal Cell Carcinoma Via Transcriptional Repression of E2F1

Supplementary Tables from A Feedback Circuitry Between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis